Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance
In recent years, the immunotherapy based on the blocking of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has achieved encouraging progress in the treatment of malignant tumors such as melanoma and lung cancer. More and more studies have focused on its role in hepatocellular ca...
Main Authors: | YANG Liu, ZHU Xiling, LI Gong |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2016-08-01
|
Series: | Linchuang Gandanbing Zazhi |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=7631 |
Similar Items
-
Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
by: Gu X, et al.
Published: (2016-08-01) -
Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression
by: Akira Asai, et al.
Published: (2020-08-01) -
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
by: Haotian Liao, et al.
Published: (2019-09-01) -
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
by: Dong-Jun Park, et al.
Published: (2021-04-01) -
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma
by: Norifumi Iseda, et al.
Published: (2021-04-01)